Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epidermolysis Bullosa Clear all
Recruiting No phase listed Observational

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573
View directory record Official record
Conditions
Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Interventions
Filsuvez
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Completed Phase 1 Interventional

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

NCT02793960
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
topical BPM31510 3.0% Cream
Drug
Lead sponsor
Shasa Hu
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Nov 10, 2026, 9:58 PM EST
Completed Phase 1 Interventional

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

NCT05062070
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
TolaSure Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 10, 2026, 9:58 PM EST
Completed Phase 1Phase 2 Interventional Results available

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

NCT01263379
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Nov 10, 2026, 9:58 PM EST
Terminated Phase 2 Interventional Results available

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

NCT02090283
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (6%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Nov 10, 2026, 9:58 PM EST
Recruiting No phase listed Observational

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

NCT01019148
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Terminated Phase 1Phase 2 Interventional

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

NCT03605069
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions
QR-313, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Nov 10, 2026, 9:58 PM EST
Not yet recruiting Phase 2 Interventional

Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex

NCT07756138
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
Filsuvez
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Months and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Withdrawn No phase listed Observational

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

NCT04214002
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Nov 10, 2026, 9:58 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Computational Drug Repurposing for All EBS Cases

NCT03269474
View directory record Official record
Conditions
Epidermolysis Bullosa, Healthy, Genetic Skin Disease, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions
Experimental Group
Procedure
Lead sponsor
Joyce Teng
Other
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Nov 10, 2026, 9:58 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132
View directory record Official record
Conditions
Generalized Epidermolysis Bullosa Simplex
Interventions
AC-203, Vehicle
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
6 Months and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin

NCT02592954
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex, Pachyonychia Congenita
Interventions
Jojoba oil with broccoli sprout extract, Jojoba oil (placebo)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Nov 10, 2026, 9:58 PM EST
Completed Phase 2 Interventional Results available

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

NCT01538862
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Granulocyte Colony Stimulating Factor (GCSF)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Nov 10, 2026, 9:58 PM EST
Completed Early Phase 1 Interventional

Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution

NCT05533866
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
APR-TD011
Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 10, 2026, 9:58 PM EST
Active, not recruiting Phase 3 Interventional

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
D-Fi
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
4
States / cities
Redwood City, California • Santa Margarita, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Completed No phase listed Observational

Short Term Observational Study in DEB Patients

NCT02178969
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Nov 10, 2026, 9:58 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Recruiting Phase 1Phase 2 Interventional

MSC EVs in Dystrophic Epidermolysis Bullosa

NCT04173650
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
AGLE-102
Drug
Lead sponsor
Aegle Therapeutics
Industry
Eligibility
6 Months and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Nov 10, 2026, 9:58 PM EST
Recruiting Phase 1Phase 2 Interventional

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

NCT06834035
View directory record Official record
Conditions
Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
Immunoglobulin G
Biological
Lead sponsor
M. Peter Marinkovich
Other
Eligibility
6 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Not listed Phase 1Phase 2 Interventional

Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT03392909
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Gentamicin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
7 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Nov 10, 2026, 9:58 PM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT02810951
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive
Interventions
FCX-007
Genetic
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
7 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 10, 2026, 9:58 PM EST
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 10, 2026, 9:58 PM EST
Not listed Phase 2 Interventional

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

NCT05157958
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
ALLO-ASC-SHEET, Vehicle Control
Biological · Other
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
4 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Nov 10, 2026, 9:58 PM EST
Completed Phase 2 Interventional

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

NCT04599881
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Redwood City, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 10, 2026, 9:58 PM EST